Jagsonpal Pharmaceuticals has entered into a Business Transfer Agreement (BTA) with Group Pharmaceuticals (Seller) on 23 September 2026, for acquisition of the Wellness Portfolio of the Seller, on a going-concern basis by way of slump sale, subject to the terms and conditions contained in the BTA.
Market Samachar is a news aggregator. This article was originally published by Share Market Today. Tap the button above to read the full story on their site.